No announcement yet.


  • Filter
  • Time
  • Show
Clear All
new posts

  • #16
    Oh, that’s sounds nice!
    Can my neurolog contact you, if she has any questions? 🙏🏻


    • #17
      I had my first Ocrevus infusion in July now it is November and I may be pregnant. How dangerous is it for the fetus if I am?


      • #18

        Probably very little risk after this long. Most, but not all, will be gone from your blood compartment by 4-5 months. Below is the data from the package insert.

        Tom Hale Ph.D.

        Risk Summary

        OCREVUS is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier. There are no adequate data on the developmental risk associated with use of OCREVUS in pregnant women. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. B-cell levels in infants following maternal exposure to OCREVUS have not been studied in clinical trials. The potential duration of B-cell depletion in such infants, and the impact of B-cell depletion on vaccine safety and effectiveness, is unknown [see WARNINGS AND PRECAUTIONS (5.2) ([url]][/url].

        Following administration of ocrelizumab to pregnant monkeys at doses similar to or greater than those used clinically, increased perinatal mortality, depletion of B-cell populations, renal, bone marrow, and testicular toxicity were observed in the offspring in the absence of maternal toxicity.

        In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

        Please note, they always use large to massive doses in animals as compared to humans.